3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
70
Lymphoma
54
Lymphoma, Large B-Cell, Diffuse
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Hodgkin Disease
26
Sarcoma
25
Lymphoma, Follicular
25
Lymphoma, Non-Hodgkin
24
Leukemia
19
Burkitt Lymphoma
17
Multiple Myeloma
16
Endometrial Neoplasms
15
Neuroblastoma
14
Ovarian Neoplasms
12
Carcinoma, Hepatocellular
12
Lymphoma, Large-Cell, Immunoblastic
11
Lymphoma, Mantle-Cell
10
Liposarcoma
9
Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Leiomyosarcoma
8
Histiocytoma, Malignant Fibrous
8
Urinary Bladder Neoplasms
7
Lymphoma, B-Cell, Marginal Zone
7
Hemangiosarcoma
7
Fibrosarcoma
7
Wilms Tumor
6
Triple Negative Breast Neoplasms
6
Sarcoma, Synovial
6
Neurofibrosarcoma
6
Interventions
Rituximab
2
Epoetin Alfa
2
Early Intervention, Educational
2
Dexamethasone
2
Darbepoetin alfa
2
Bortezomib
2
ponatinib
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ibritumomab tiuxetan
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
cirmtuzumab
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Vorinostat
1
Vincristine
1
Sucrose
1
Prednisone
1
Methotrexate
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Etoposide
1
Doxorubicin
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoproliferative Disorders
×
Doxorubicin
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled